ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
First Wave BioPharma Inc

First Wave BioPharma Inc (FWBI)

5.17
-0.06
(-1.15%)
Closed February 20 04:00PM
5.17
0.00
( 0.00% )
Pre Market: 07:04AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
5.17
Bid
5.07
Ask
5.90
Volume
42
0.00 Day's Range 0.00
2.75 52 Week Range 87.20
Market Cap
Previous Close
5.17
Open
-
Last Trade
1
@
5.17
Last Trade Time
07:00:00
Financial Volume
-
VWAP
-
Average Volume (3m)
898,976
Shares Outstanding
674,999
Dividend Yield
-
PE Ratio
-0.23
Earnings Per Share (EPS)
-22.18
Revenue
8.09M
Net Profit
-14.97M

About First Wave BioPharma Inc

First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietar... First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
First Wave BioPharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FWBI. The last closing price for First Wave BioPharma was $5.17. Over the last year, First Wave BioPharma shares have traded in a share price range of $ 2.75 to $ 87.20.

First Wave BioPharma currently has 674,999 shares outstanding. The market capitalization of First Wave BioPharma is $3.49 million. First Wave BioPharma has a price to earnings ratio (PE ratio) of -0.23.

FWBI Latest News

First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024

BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in th...

First Wave BioPharma to Present at the DealFlow MicroCap Conference

BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in th...

First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico

BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in th...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.112.173913043485.065.54.9458645.18260505CS
41.3434.98694516973.835.7983.421381404.91672685CS
120.377.708333333334.814.512.758989765.35199868CS
26-2.432-31.99158116297.60222.22.7522509628.66249521CS
52-70.43-93.161375661475.687.22.75160988615.04842481CS
156-477.83-98.92960662534836862.75155139098.72058413CS
260-477.83-98.92960662534836862.75155139098.72058413CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GBNHGreenbrook TMS Inc
$ 0.53
(173.20%)
16.87M
SOGPSound Group Inc
$ 7.09
(146.61%)
2.77M
EFOIEnergy Focus Inc
$ 2.26
(75.19%)
3.45M
CNEYCN Energy Group Inc
$ 2.33
(75.19%)
9.17M
MOTSMotus GI Holdings Inc
$ 0.8801
(34.92%)
4.39M
ATIFATIF Holdings Ltd
$ 0.705
(-37.61%)
3
CPOPPop Culture Group Company Ltd
$ 4.98
(-30.74%)
249.35k
AVGRAvinger Inc
$ 4.00
(-26.59%)
10.34k
BFRIBiofrontera Inc
$ 0.89
(-22.61%)
110.48k
PANWPalo Alto Networks Inc
$ 283.50
(-22.56%)
235.65k
GBNHGreenbrook TMS Inc
$ 0.53
(173.20%)
16.87M
KTRAKintara Therapeutics Inc
$ 0.10125
(3.32%)
14.01M
CNEYCN Energy Group Inc
$ 2.33
(75.19%)
9.17M
IVPInspire Veterinary Partners Inc
$ 0.1686
(25.63%)
8.63M
AFIBAcutus Medical Inc
$ 0.27
(12.50%)
5.19M

FWBI Discussion

View Posts
Awl416 Awl416 2 months ago
New pm highs
👍️0
Animas Animas 2 months ago
interesting turn in events.
👍️0
Monksdream Monksdream 2 months ago
Didn’t waste no time diluting
👍️0
TheFinalCD TheFinalCD 2 months ago
https://ih.advfn.com/stock-market/NASDAQ/first-wave-biopharma-FWBI/stock-news/92895157/form-s-1-a-general-form-for-registration-of-secu
👍️0
TheFinalCD TheFinalCD 2 months ago
S-1 killing this -9 from hi
👍️0
subslover subslover 2 months ago
Very true to form.
👍️0
Monksdream Monksdream 2 months ago
Back down in 2024
👍️0
TheFinalCD TheFinalCD 2 months ago
$FWBI NOV 2023 S-1 DILUTION Overall Risk
High
Offering Ability
High
Overhead Supply
High
Historical
High
Cash Need
High




https://dilutiontracker.com/app/search/FWBI
👍️0
Monksdream Monksdream 2 months ago
Trading soon
👍️0
Awl416 Awl416 2 months ago
Fun
👍️0
Monksdream Monksdream 2 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
TheFinalCD TheFinalCD 2 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173507523&txt2find=fwbi
👍️0
subslover subslover 2 months ago
GM bro! :)
👍️0
TheFinalCD TheFinalCD 2 months ago
NEW HIGHS FOR THIS MICRO FLOATER

FWBI NEWS https://www.globenewswire.com/news-release/2023/12/27/2801297/0/en/First-Wave-BioPharma-Announces-Streamlining-of-Clinical-Pipeline-with-Non-Binding-Term-Sheet-to-Sell-Niclosamide-IBD-Program.html
👍️0
TheFinalCD TheFinalCD 2 months ago
gm & thx

$FWBI
BOCA RATON, Fla
👍️0
subslover subslover 2 months ago
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and related conditions to an undisclosed biopharmaceutical company (the “Proposed Transaction”). The Proposed Transaction will enable First Wave BioPharma to focus its development resources on its three late-stage clinical programs: Capeserod, a selective 5-HT4 receptor partial agonist licensed from Sanofi; Adrulipase, a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI); and, after the closing of the recently announced potential business combination with ImmunogenX, Latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease.

The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties. The transaction is expected to close in the first half of 2024. Additional details of the transaction will be disclosed upon finalization and execution of the definitive agreement. Upon execution of the definitive agreement, the completion of the transaction will be subject to, among other matters, satisfaction of the conditions negotiated therein, the buyer having secured adequate financing, and receipt of all third party (including governmental) approvals, licenses, consents, and clearances, as and when applicable.

“This is a very exciting time in the evolution of First Wave BioPharma as we have recently reinvigorated our GI-focused clinical development pipeline with Phase 2-ready Capeserod from Sanofi and the pending addition of Phase 3-ready Latiglutenase,” stated James Sapirstein, President and CEO of First Wave BioPharma. “We plan to rapidly advance these programs in 2024 given the significant potential of each to address GI conditions for which no effective therapies currently exist. As a result, we made the strategic decision to streamline our development pipeline and are pleased to have entered a non-binding term sheet for Niclosamide, which has the potential to infuse First Wave with additional, non-dilutive capital.”

Niclosamide is a prescription, non-systemic, small molecule drug listed as an essential medicine by the World Health Organization (WHO). Niclosamide was approved by the U.S. Food and Drug Administration (FDA) in 1982 for the treatment of intestinal tapeworm infections and has been safely used on millions of patients. The drug is a potential non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate inflammatory bowel diseases (IBD). First Wave BioPharma had previously conducted Phase 2 trials with niclosamide for the treatment of ulcerative proctitis/proctosigmoiditis (the most prevalent form of ulcerative colitis) and for the treatment of COVID gastrointestinal infections. The Company also has a Phase 2 open-IND for the treatment of immune checkpoint inhibitor-associated colitis and diarrhea in patients with metastatic cancer. Intellectual property for niclosamide formulations governing composition of matter and methods of use extends beyond 2040.

About First Wave BioPharma, Inc.

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical stage programs, including Capeserod, a selective 5-HT4 receptor partial agonist which First Wave is developing for gastrointestinal (GI) indications; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; and it is anticipated that the Company will soon acquire Latiglutenase, a targeted, oral first-in-class biotherapeutic for celiac disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether a definitive agreement for the Proposed Transaction or a transaction with ImmunogenX and any concurrent financing or licensing transaction will be entered into; whether such transactions, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of the Proposed Transaction described herein; the Company’s ability to integrate the assets and commercial operations contemplated to be acquired from ImmunogenX into the Company’s business; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with
👍️0
Awl416 Awl416 2 months ago
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
👍️0
Disquisition Disquisition 2 months ago
Yes
👍️0
SILVERSURFER4263 SILVERSURFER4263 2 months ago
did this recently do another r/s?
👍️0
Disquisition Disquisition 2 months ago
ATROCIOUS DUMPING
👍️0
stock1ace1 stock1ace1 4 months ago
Fwbi .36
👍️0
Hercules1 Hercules1 4 months ago
Run to dollars is on now.
👍️0
Hercules1 Hercules1 4 months ago
Big conference presentation is tomorrow by the CEO.

This is the next big runner.

Price target: $11

Massively undervalued just like TPST.
👍️0
2020Benzo 2020Benzo 4 months ago
Looks primed to run now
👍️0
hondaboost hondaboost 5 months ago
FWBI, Bad news: Financing at $0.43: LOL!

2023-09-14 10:44 ET - News Release
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 5,882,036 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $0.43 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.0 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.
👍️0
TheFinalCD TheFinalCD 5 months ago
First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering
https://finance.yahoo.com/news/first-wave-biopharma-inc-announces-121500394.html
👍️0
TheFinalCD TheFinalCD 5 months ago
Common Stock Morgan Stanley
1 New York Plaza
38th Fl.
New York NY 10004
7,152,204 08/31/2023
Nasdaq


https://www.firstwavebio.com/tmp/dd1816af9e4e1e15974ac2972280ac3ba6d6202cefc0032c61d411270c518648.pdf
👍️0
TheFinalCD TheFinalCD 5 months ago
WOW STARTED BOUNCING EOD .57 THEN QUICK HARD DUMP TO .48


PRETTY SICK

HOW & WHY?

I DUNNO
👍️0
TheFinalCD TheFinalCD 5 months ago
YEP i LOST A CHUNK ON THIS ONE, GOT FOOLED THINKING THE BOTTOM WAS IN @ .60 AFTER HITTING 1.11

SOMETHING IS VERY WRONG EVEN IF THERE ARE 11M SHARES ADDED TO THE 7M THE HAD BEFORE THE WARRANTS

18M SHARES=12M=30M, THERE IS 128M VOLUME

THATS CLOSE TO 100M MORE = HOW IN THE WORLD>??????

AND BASICALLY NO BOUNCE

IVE SEEN SOME DO A "V" BOUNCE

THIS ONE IS A FLAT LINER

WHY I DO NOT KNOW

THE SANOFI NEWS IS SOLID

https://finance.yahoo.com/news/first-wave-biopharma-announces-exclusive-100000787.html
👍️0
Invest-in-America Invest-in-America 5 months ago
FWBI: No wonder I trashed this crap months ago! (The IDENTICAL routine; but this time they gots a REAL CONTRACT???? To SELL their insider SHARES???)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172121453
👍️0
Awl416 Awl416 5 months ago
The fact algo’s allowed this to get above a buck today is just as mind boggling when lets be honest they knew a offering was coming
👍️0
Awl416 Awl416 5 months ago
Unfortunately…..They don’t care about mom n pop traders

Big boys on wallstreet make money they satisfied

👍️0
SILVERSURFER4263 SILVERSURFER4263 5 months ago
how the sec and nasdaq dont halt these crime scenes is mind boggling
👍️0
Awl416 Awl416 5 months ago
I mean just look at the chart. This isn’t shocking….
👍️0
SILVERSURFER4263 SILVERSURFER4263 5 months ago
boca raton based crooked ceo..figures
👍️0
Invest-in-America Invest-in-America 5 months ago
Not "back in", but for the FIRST time today, Bro --- since I too suspect that this could be that late market soaring freak show routine!
👍️0
INFINITI INFINITI 5 months ago
I might just get back in
👍️0
INFINITI INFINITI 5 months ago
They let it rise to $1.11 only to release this news bunch of crooks
👍️0
SILVERSURFER4263 SILVERSURFER4263 5 months ago
just another pump and dump i see...thanks.
👍️0
SILVERSURFER4263 SILVERSURFER4263 5 months ago
there is NO SEC to protect investors anymore.
👍️0
Invest-in-America Invest-in-America 5 months ago
FWBI: Grab this RIGHT NOW --- better yet was circa 30-minutes ago --- and you will likely DOUBLE your bet by the Close today!!
👍️0
TheFinalCD TheFinalCD 5 months ago
ITS MIND BOGGLING HOW THEY HAD 7M SHARES AND IT WENT TO 1.11

THEN 11M WARRANTS TAKE IT DOWN TO .59

THE FREAKIN VOLUME IS 10X THAT

SMH
👍️0
dande1990 dande1990 5 months ago
Its the way it is on all these biopharma stocks. I saw this Premarket moving... in at .75 set a sell at .85. It happened in a blink. Watching it go up to 1.11 I was kicking myself but not anymore!!

$FWBI
👍️0
Invest-in-America Invest-in-America 5 months ago
FWBI: Well then, CONGRATS, Boss!!! How much you SCORE today on this one??? INSPIRE US!!!

Sincerely yours,

"That Nut Job"
San Diego, CA
👍️0
TheFinalCD TheFinalCD 5 months ago
A SHORTERS DREAM SITUATION POP OVER $1 ON HYPE PUMP, THEN SLASH & CRASH, WITH THE HELP OF COMPANY NEWS

WELCOME THE THE THUNDER DOME
👍️0
Invest-in-America Invest-in-America 5 months ago
FWBI: I need their stuff, RIGHT NOW!!!! (I could be a 'Control Group' of just one guy!!)

PS: If whomever does NOT like my humor, well, then EAT-SHIT-&-DIE!!!! (And then see if some Stinky Pinky Company has a VACCINE for that kind of self-inflicted DISEASE!!!)
👍️0
Awl416 Awl416 5 months ago
ding ding ding

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market
👍️0
TheFinalCD TheFinalCD 5 months ago
.43 priced WARRANTS $FWBI First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market

https://www.globenewswire.com/news-release/2023/09/14/2743459/0/en/First-Wave-BioPharma-Announces-Exercise-of-Warrants-and-Issuance-of-New-Warrants-in-a-Private-Placement-for-4-0-Million-Gross-Proceeds-Priced-At-the-Market.html
👍️0
TheFinalCD TheFinalCD 5 months ago
On September 13, 2023, ZyVersa Therapeutics, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with a holder (the “Holder”) of warrants to purchase shares of the Company’s common stock (the “Existing Warrants”) pursuant to which the Holder agreed to exercise for cash their Existing Warrants to purchase up to 12,121,213 shares of the Company’s common stock, at a Reduced Exercise Price (as defined below) during the period from September 13, 2023 until 5:30 p.m., Eastern Time, on September 18, 2023 (the “Reduced Price Exercise Period”), in exchange for the Company’s agreement to issue new warrants (the “Inducement Warrants”) on substantially the same terms as the Existing Warrants as described below, to purchase up to 12,121,213 shares of the Company’s common stock (the “Inducement Warrant Shares”). Pursuant to the Inducement Letter, upon the exercise of any Existing Warrants, the reduced exercise price for such Existing Warrants during the Reduced Price Exercise Period shall be the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the day of an exercise of Existing Warrants; or (ii) the average Nasdaq Official Closing Price of the Common Stock (as reflected on Nasdaq.com) for the five (5) Trading Days immediately preceding the day of an exercise of Existing Warrants (the “Reduced Exercise Price”).
👍️0
INFINITI INFINITI 5 months ago
Out thk you for the 1.07 on to the next GL everyone
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com